Recruiting

New antibody treatments after immune cell therapy for aggressive lymphoma

Plain-English translation of NCT04889716 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing two experimental approaches to fight aggressive B-cell lymphoma. After you receive CAR-T cell therapy (immune cells genetically modified to recognize and attack cancer), you will receive either (in Cohort 1) or a combination of and (in Cohort 2). The goal is to see if adding these new antibody medications after CAR-T cells can improve outcomes and keep the cancer from returning.

Some patients with aggressive lymphoma find that their cancer comes back or never fully responds to standard treatments, leaving them with limited options. This trial is exploring whether combining CAR-T cell therapy with newer antibody medications might work better than either treatment alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma that has come back after or failed to respond to prior treatments
you have already received CAR-T cell therapy and are at least 30 days past your CAR-T infusion
you have measurable disease visible on imaging scans within the required timeframe
you have a life expectancy of at least 12 weeks
you have received prior treatments that included both chemotherapy and anti-CD20 therapy

You likely don't qualify if…

you experienced severe side effects (Grade 3 or higher cytokine release syndrome or Grade 2 or higher neurologic problems) from your CAR-T cell therapy that have not resolved
you are pregnant, breastfeeding, or planning to become pregnant in the next 18 months
you have a history of serious allergic reactions to monoclonal antibody therapies
you have significant heart or lung disease requiring ongoing oxygen or steroid use
you have an active infection (bacterial, viral, or fungal) at the time of enrollment

What participation looks like

You will receive the experimental antibody medication through infusions over several treatment cycles. In Cohort 1, you will receive at higher doses in the first two cycles, then lower doses in later cycles. In Cohort 2, you will receive a combination of two medications with the first cycle given over two weeks at a lower dose to start. The study team will monitor you closely with blood tests and imaging scans to track how well the treatment is working and to watch for side effects.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(2 sites)

United States

University of Nebraska Medical Center, Omaha, Nebraska

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania